newsfilter
← Latest News
GlobeNewswire·

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTX
  • Enrollment is ongoing in Ntrust-1 and Ntrust-2 trials at the 4 billion cell dose level (12 billion total cells in a 3-dose cycle) across all autoimmune indications.
  • An FDA regulatory agreement supports protocol amendments allowing outpatient dosing in community settings, re-dosing options, & removal of overnight monitoring requirements.
  • The Ntrust-2 study has been expanded to include patients with rheumatoid arthritis following IRB approvals at multiple sites.
  • Initial clinical data from both Ntrust-1 and Ntrust-2 is expected to be presented at a medical meeting in 2026.
  • The company reported a cash balance of $266.7 million as of March 31, 2026, which is projected to fund operations into 2029.
  • First quarter 2026 research & development expenses were $25.0 million, while general & administrative expenses were $5.9 million.
  • The company reported a net loss of $27.8 million for the first quarter of 2026, equivalent to $0.37 per share.
  • NKX019 is an allogeneic CAR-NK cell therapy engineered to target CD19-positive B cells without requiring supplemental cytokines.
  • Patients in the trials receive a three-dose cycle on Days 0, 3, & 7 following lymphodepletion with fludarabine & cyclophosphamide.